To address above issues, specific experimental approaches need to be taken: (1) Generating various TP53MUT constructs, introducing them into HMCLs with very low or undetectable p53 to make stable expression, followed by analysis of miRNA profiling with or without anti-myeloma drugs. The gene discussed is TP53; the disease is plasma cell myeloma.